Jiangsu Hengrui Medicine
600276.SS
£5.51
Share price
5.28%
Change (1 day)
8.53%
Change (1 year)
Categories
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics
Revenue for Jiangsu Hengrui Medicine (600276.SS)
Revenue in 2024 (TTM): £2.83 Billion
According to Jiangsu Hengrui Medicine
's latest financial reports the company's current revenue (TTM 
) is £2.81 Billion. In 2023 the company made a revenue of £2.52 Billion a decrease over the revenue in the year 2022 that were of £2.60 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Jiangsu Hengrui Medicine from 2002 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 (TTM) | £2.83 B | 12.06% |
| 2023 | £2.52 B | -2.87% |
| 2022 | £2.60 B | -12.25% |
| 2021 | £2.96 B | -0.46% |
| 2020 | £2.97 B | 16.37% |
| 2019 | £2.55 B | 24.57% |
| 2018 | £2.05 B | 34.4% |
| 2017 | £1.52 B | 13.48% |
| 2016 | £1.34 B | 35.27% |
| 2015 | £0.99 B | 28.69% |
| 2014 | £0.77 B | 26.03% |
| 2013 | £0.61 B | 14.88% |
| 2012 | £0.53 B | 17.14% |
| 2011 | £0.45 B | 26.42% |
| 2010 | £0.36 B | 31.59% |
| 2009 | £0.27 B | 15.49% |
| 2008 | £0.23 B | 80.7% |
| 2007 | £0.13 B | 42.69% |
| 2006 | £92.11 M | 10% |
| 2005 | £83.73 M | 20.92% |
| 2004 | £69.25 M | -2.47% |
| 2003 | £71 M | 24.61% |
| 2002 | £56.98 M |